Catalyze Interviews Vector Bioscience’s CEO, Lluna Gallego, on Advancing RNA Delivery in Oncology
We are pleased to share a recent interview with our CEO and Co-Founder, Lluna Gallego, conducted by Catalyze,
March 6, 2026
The most versatile targeted delivery
Deploying breakthrough research from Cambridge to tangible applications
Vector's Science
Vector Bioscience develops a machine-learning empowered drug delivery platform. We are dedicated to transforming oncology treatments with our cargo-agnostic technology. Our precision-targeted delivery minimizes side effects with a higher uptake and slow release. By tailoring delivery, we achieve high local concentrations of traditionally difficult-to-formulate therapeutics.
How our technology works
Data
Data-driven selection of cargoes & customisation for specific cancers
Dry Lab
ML-enabled material selection
Wet Lab
Engineering of cargo and drug loading
Novel Medical Treatment
Personalized & precision medicines
About our Nanoshutle technology
the people behind Vector
Vector Team
Advisory Board
Biology & IP
Oncology & Clinical Trials
Formulation & Drug Delivery
Modalities
Our Culture
We believe in pushing boundaries, prioritising excellence. We have the top experts, specialists, scientists (and data!) are part of our team. Together, we work to progress Vector’s nanoparticle shuttle to the clinic. Our technology pioneers the future oncology treatment and our drive is to bring it to patients, improving treatments and their quality of life.
Vision
We are providing the ultimate precision medicine, enacting a paradigm change in drug therapy development. Through pioneering tomorrow’s therapies we are building a future where we do not fear cancer.
Mission
We want to improve treatments for patients maximising efficacy and minimising side-effects and bringing the 3 Ls to life:
Low side-effects
Localised delivery – directly to where treatment is needed
Loading – greater uptake of drugs
Pipeline
We’re committed to delivering novel treatments to rare disease patients
ML identification
Formulation & delivery
In vitro studies
In vivo studies
Clinical planning
Partner confirmation
Biocompatibility
Currently in: In vivo studies
Pancreatic Cancer
Currently in: In vivo studies
Triple Negative Breast Cancer
Currently in: In vivo studies
Mesothelioma
Currently in: In vivo studies
Lung Cancer
Currently in: In vivo studies
What’s New In The Field And Our Labs
The Nobel Prize for MOFs: A milestone for reticular chemistry and for the future of drug delivery
This year’s Nobel Prize in Chemistry has been awarded to the pioneers of MOFs, recognising a class of
February 6, 2026
Vector Bioscience Cambridge Joins the Future Medicines Accelerator
Vector Bioscience Cambridge has been selected to join the Future Medicines Accelerator, a programme delivered by LYVA Labs
November 12, 2025
Some of our partners and collaborators
Get in touch to explore opportunities. Partner with us
Address
Vector Bioscience Cambridge
The Hauser Forum
3, Charles Babbage Rd
CB3 0GT Cambridge
United Kingdom
Mail Address
contact@vectorbiocam.com